Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Evaxion Biotech A/S > Profile

Evaxion Biotech A/S (EVAX)

Market is closed
Sector: Healthcare

Hedge Fund Popularity

13F filing is ongoing

Hedge Fund Holdings
Filing Period:
Last update:
No. Hedge Fund Shares Value Activity % Port
1.
Ikarian Capital

Neil Shahrestani

 74,698 $356,310 -7% 0.03%
2.
Point72 Asset Management

Steve Cohen

 33,100 $157,887 0%
3.
Stonepine Capital

Timothy P. Lynch

 20,000 $95,400 0.07%
Institutional Investors' Holdings
Filing Period:
No. Name Shares Value % Port
1.
Merck & Co., Inc.
 1,214,126 $5,791,381 2.1%
2.
Rhumbline Advisers
 21,090 $100,592 0%
3.
Boothbay Fund Management, Llc
 18,426 $87,892 0%
4.
Smartharvest Portfolios, Llc
 15,194 $72,475 0.03%
5.
Wesbanco Bank Inc
 10,000 $47,700 0%
News See All

Evaxion Biotech A/S (NASDAQ:EVAX) Q3 2025 Earnings Call Transcript

Operator: Hello, and welcome to the Evaxion Business Update and Third Quarter 2025 Financial Results. [Operator Instructions] Please be advised that today's conference is being recorded.

Keep Reading →

November 8th, 2025 - News Transcripts

Lake Street Raises Evaxion (EVAX) PT to $11 Following Positive Two-Year EVX-01 Melanoma Data

Lake Street Raises Evaxion (EVAX) PT to $11 Following Positive Two-Year EVX-01 Melanoma Data

Evaxion (NASDAQ:EVAX) is one of the hot stocks to buy with huge upside potential.

Keep Reading →

October 26th, 2025 - News

12 Hot Stocks to Buy with Huge Upside Potential

12 Hot Stocks to Buy with Huge Upside Potential

On October 22, Vios Advisors’ Michael Bapis and BNY’s Alicia Levine joined CNBC's 'Closing Bell' to discuss the latest news affecting markets.

Keep Reading →

October 24th, 2025 - Hedge Funds News

Evaxion Biotech A/S (NASDAQ:EVAX) Q2 2025 Earnings Call Transcript

Operator: Hello, and welcome to Evaxion's Second Quarter 2025 Conference Call. [Operator Instructions] I would now like to turn the conference over to Birgitte Rono, Interim CEO and CSO.

Keep Reading →

August 20th, 2025 - News Transcripts

Evaxion Biotech Receives Grant Funding to Develop New Polio Vaccine

Evaxion Biotech Receives Grant Funding to Develop New Polio Vaccine

The funds will be used to support research into identifying and combining antigens to create a new vaccine design that does not utilize live viruses.

Keep Reading →

June 4th, 2025 - News

Evaxion Biotech A/S (NASDAQ:EVAX) Q1 2025 Earnings Call Transcript

Operator: Good day, and thank you for standing by. Welcome to the Evaxion First Quarter 2025 Conference Call and Webcast. At this time, all participants are in a listen-only mode.

Keep Reading →

May 28th, 2025 - News Transcripts

Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2024 Earnings Call Transcript

Operator: Good day, and thank you for standing by. Welcome to the Evaxion Biotech Business Update Full Year 2024 Conference Call and Webcast.

Keep Reading →

April 4th, 2025 - News Transcripts

Evaxion Biotech A/S (NASDAQ:EVAX) Q2 2024 Earnings Call Transcript

Operator: Good day and thank you for standing by. Welcome to the Evaxion Biotech Business Update Conference call. [Operator Instructions] Please be advised, that today's conference is being recorded.

Keep Reading →

August 15th, 2024 - News Transcripts

Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript

Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript

Christian Kanstrup: Hello, everyone, and a very warm welcome to this Evaxion Business Update Conference call on the back of our Full Year 2023 Results. I'm Christian Kanstrup. I'm the CEO of Evaxion.

Keep Reading →

April 3rd, 2024 - News Transcripts

Evaxion Biotech A/S (NASDAQ:EVAX) Q2 2023 Earnings Call Transcript

Evaxion Biotech A/S (NASDAQ:EVAX) Q2 2023 Earnings Call Transcript

Operator: Good day, and thank you for standing by. Welcome to the Evaxion Biotech Q2 Results Call. At this time, all participants are in a listen-only mode.

Keep Reading →

August 23rd, 2023 - News Transcripts

Click here to See All News
Insider Monkey Quarterly Strategy
+427.7% Insider Monkey Quarterly Strategy
+163.1% Benchmark50% S&P 500 ETF and 50% Russell 2000 ETF
400%
200%
0%

Returns since its inception in May 2014 (through August 15th, 2025)

Subscribe Now

30 day money back guarantee. Cancel anytime.